Long‐term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e‐antigen seroclearance
James Fung, Ka‐Shing Cheung, Danny Ka‐Ho Wong, Lung‐Yi Mak, Wai‐Pan To, Wai‐Kay Seto, Ching‐Lung Lai, Man‐Fung Yuen – 13 March 2018 – The significance of hepatitis B e‐antigen (HBeAg) seroclearance (ESC) in the long term is not well defined. The current study aimed to determine the clinical outcomes, the factors and predictive scores for hepatocellular carcinoma (HCC), and hepatitis B surface antigen (HBsAg) seroclearance of a large cohort of patients undergoing ESC. Patients with documented ESC were followed up 3‐ to 6‐monthly.